Evidence map›Paper›PMID 42544221›Full record

ArticleGlobal cardiology science & practice2026

Catheter ablation versus no ablation for atrial fibrillation in cardiac amyloidosis: a propensity-matched cohort study.

Joud Fahed, Mohammad Hamza, Azka Naeem, Asad Ur Rab, Muhammad Hashim Khan, Mohammad Ali Sheffeh, Jawad Basit, Salem Assiri, M Chadi Alraies

Abstract read
In one paragraph

Article in Global cardiology science & practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joud FahedDepartment of Medicine, Ascension Saint Agnes Hospital, Baltimore, Maryland, USA.
Mohammad HamzaDepartment of Hospital Medicine, Guthrie Cortland Regional Medical Center, Cortland, NY, USA.
Azka NaeemAdvanced Cardiac Imaging Department, St. Francis Hospital and Heart Center, Roslyn, New York, USA.
Asad Ur RabDepartment of Medicine, Foundation University Medical College, Islamabad 44000, Pakistan.
Muhammad Hashim KhanDepartment of Medicine, Maimonides Medical Center, Brooklyn, New York, USA.
Mohammad Ali SheffehDepartment of Medicine, Henry Ford, Warren, Michigan, USA.
Jawad BasitDepartment of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Salem AssiriKing Fahad Armed Forces Hospital, Ministry of Defense Health Services, Jeddah, Saudi Arabia.
M Chadi AlraiesDepartment of Interventional Cardiology, Detroit Medical Center/Wayne State University, MI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtrial fibrillation (AF) is extremely common in cardiac amyloidosis (CA) due to amyloid infiltration and atrial electrical remodeling. We aim to compare ablation outcomes versus no-ablation in patients taking anti-arrhythmic drugs (AAD) in CA-associated AF.

methodsUsing TriNetX database (2019-2025), 5,562 patients with CA and AF were identified and divided into two groups: catheter ablation plus AADs (

results870 patients were included in each cohort. At 12-month follow-up, catheter ablation was associated with a significantly lower risk of the composite outcome (8.3% vs 13.2%; HR 0.591, 95% CI [0.418-0.834],

conclusionCatheter ablation was associated with improved short-term outcomes despite higher arrhythmia recurrence. Ablation may be considered in carefully selected patients, particularly those with earlier-stage disease or significant symptoms.

Identifiers

PMID42544221
PMCPMC13429178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.